Stockreport

BiomX outlines imminent FDA feedback and targets BX004 Phase IIb data in Q1 2026 while advancing BX011 for diabetic foot infections [Seeking Alpha]

BiomX Inc. COmmon Stock  (PHGE) 
PDF Jonathan Solomon, CEO, stated that the third quarter of 2025 was an important period for BiomX, highlighting that "we began the quarter strongly with first patient dosi [Read more]